{"nctId":"NCT00418457","briefTitle":"Regional Anesthesia and Breast Cancer Recurrence","startDateStruct":{"date":"2007-01"},"conditions":["Breast Neoplasms"],"count":2108,"armGroups":[{"label":"General anesthesia and opioid","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: General anesthesia and opioids"]},{"label":"Regional analgesia and propofol","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Regional analgesia and propofol"]}],"interventions":[{"name":"General anesthesia and opioids","otherNames":["General anesthesia"]},{"name":"Regional analgesia and propofol","otherNames":["Regional analgesia"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Primary breast cancer without known extension beyond the breast and axillary nodes (i.e. believed to be Tumor Stage 1-3, Nodes 0-2)\n* Scheduled for unilateral or bilateral mastectomy with or without implant (isolated \"lumpectomy\" will not qualify)\n* Isolated \"lumpectomy\" with axillary node dissection (anticipated removal of at least five nodes)\n* Written informed consent, including willingness to be randomized to morphine or regional analgesia\n\nExclusion Criteria:\n\n* Previous surgery for breast cancer (except diagnostic biopsies)\n* Inflammatory breast cancer\n* Age \\< 18 or \\> 85 years old\n* Scheduled free flap reconstruction\n* ASA Physical Status ≥ 4\n* Any contraindication to epidural or paravertebral anesthesia and analgesia (including coagulopathy, abnormal anatomy)\n* Any contraindication to midazolam, propofol, sevoflurane, fentanyl, or morphine\n* Other cancer not believed by the attending surgeon to be in long-term remission\n* Systemic disease believed by the attending surgeon to present ≥ 25% two-year mortality","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Had Breast Cancer Recurrence After Breast Cancer Surgery","description":"time to breast cancer recurrence from the end of surgery.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"102","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants That Experienced Post-Surgical Pain","description":"Brief Pain Inventory is used to evaluate with values of any pain vs. no pain (binary)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"456","spread":null},{"groupId":"OG001","value":"442","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"232","spread":null},{"groupId":"OG001","value":"239","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants That Experienced Neuropathic Pain After Surgery","description":"neuropathic pain is a binary outcome: any pain vs. no pain","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"SF-12 PCS Score","description":"Physical and Mental Health Composite Scores (PCS \\& MCS) are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.7","spread":"8.1"},{"groupId":"OG001","value":"49.8","spread":"8.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.3","spread":"6.7"},{"groupId":"OG001","value":"52.1","spread":"7.3"}]}]}]},{"type":"SECONDARY","title":"SF-12 MCS Score","description":"Physical and Mental Health Composite Scores (PCS \\& MCS) are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","spread":"8.6"},{"groupId":"OG001","value":"48.7","spread":"8.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":"9.7"},{"groupId":"OG001","value":"48.7","spread":"9.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":1065},"commonTop":[]}}}